RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
Verve Therapeutics Analyst Ratings
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline
Buy Rating on Verve Therapeutics: Promising Gene Editing Prospects and Anticipated Recovery
Verve Therapeutics Analyst Ratings
Buy Rating Affirmed for Verve Therapeutics With Strategic Focus on Promising VERVE-102 Program
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Clinical Studies and Strategic Advancements
Verve Therapeutics Analyst Ratings
RBC Capital Sticks to Their Buy Rating for Verve Therapeutics (VERV)
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
Verve Therapeutics' Robust Financial Performance and Promising Future Prospects: A Buy Rating Justified
Analysts' Top Healthcare Picks: Vigil Neuroscience Inc (VIGL), Verve Therapeutics (VERV)
Strong Buy Rating for Verve Therapeutics: Influenced by Eli Lilly's Acquisition, Partnership Prospects, and Positive FDA Clearance
Positive Prospects for Verve Therapeutics: FDA Approval, Innovative Treatment and Promising Preliminary Data Drive Buy Rating
Analysts' Top Healthcare Picks: Verve Therapeutics (VERV), Immunovant (IMVT)
Promising Future of Verve Therapeutics: A Comprehensive Analysis Supporting the Buy Rating
Cantor Fitzgerald Reiterates Neutral on Verve Therapeutics, Maintains $22 Price Target